Associate Editor


Takashi Nomiyama, MD, PhD

Associate Professor
Department of Endocrinology and Diabetes Mellitus
School of Medicine
Fukuoka University
7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan

Biography

Education

• (1995) MD (Medicine), Juntendo University Tokyo, Japan
• (2002) PhD (Diabetology), Juntendo University Graduate School/Tokyo, Japan


Employment History

• (2012-Present) Associate Professor, Department of Endocrinology and Diabetes Mellitus, School of Medicine, Fukuoka University, Fukuoka
• (2010-2012) Senior Assistant Professor, Department of Endocrinology and Diabetes Mellitus, School of Medicine, Fukuoka University, Fukuoka
• (2009-2010) Assistant, Department of Medicine, Metabolism and Endocrinology, Juntendo University, School of Medicine, Tokyo
• (2008-2009) Assistant, Department of Internal Medicine, Division of Diabetes and Endocrinology, Juntendo Tokyo Kotoh Geriatric Medical Center
• (2005-2008) Post-Doctoral Fellow, Department of Internal Medicine, Division of Endocrinology and Molecular Medicine, University of Kentucky College of Medicine
• (2004-2005) Assistant, Department of Medicine, Metabolism and Endocrinology, Juntendo University, School of Medicine, Tokyo
• (2002-2004) Post-Doctoral Fellow, Department of Medicine, Metabolism and Endocrinology, Juntendo University, School of Medicine, Tokyo
• (1995-1998) General Internal Medicine Residency, Juntendo University Hospital, Tokyo

Research Interest

His research interests include: Diabetes and vascular biology, Incretin biology.

Scientific Activities

Awards

• (2004) Young Investigator Award of Japan Endocrinology Society
• (2006) Young Investigator Travel Award of 7th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology
• (2012) Outstanding research award of the Japanese Society of Constitutional Medicine


Grants

• (2005-2007) Suzuki Manpei foundation Post Doctoral Grant
• (2007-2008) American Heart Association Post Doctoral Grant
• (2009) Grant from Ministry of Education, Sports and Culture of Japan (21790883)
• (2009) Grant from Suzuken Memorial Foundation

Publications

1. Zhao Y, Nomiyama T, Findeisen HM, et al. Epigenetic regulation of the NR4A orphan nuclear receptor NOR1 by histone acetylation. FEBS Lett. 2014; 588(24): 4825-4830. doi: 10.1016/j.febslet.2014.11.017
2. Terawaki Y, Nomiyama T, Kawanami T, et al. Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury. Cardiovasc Diabetol. 2014; 13: 154. doi: 10.1186/s12933-014-0154-3
3. Tanabe M, Akehi Y, Nomiyama T, Murakami J, Yanase T. Total testosterone is the most valuable indicator of metabolic syndrome among various testosterone values in middle-aged Japanese men. Endocrin J. 2014. doi: 10.1507/endocrj.EJ14-0313
4. Nomiyama T, Kawanami T, Irie S, et al. Exendin-4, a glicagon-like peptide-1 receptor agonist, attenuates prostate cancer growth. Diabetes. 2014; 63(11): 3891-3905. doi: 10.2337/db13-1169
5. Masuzaki H, Takemoto N, Kawamoto E, Nomiyama T, Tanaka H, Morita M. Discussion meeting on the clinical update and topics in variety of diseases closely related with diabetes mellitus. Nihon Naika Gakkai Zasshi. 2013; 102(4): 938-954. doi: 10.2169/naika.102.938
6. Terawaki Y, Nomiyama T, Ohta C, et al. The efficacy of sitagliptin in basal supported oral therapy. Prog Med. 2013; 33: 2217-2221.
7. Murase K, Nagaishi R, Takenoshita H, Nomiyama T, Akehi Y, Yanase T. Prevalence and clinical characteristics of primary aldosteronism in Japanese patients with type 2 diabetes mellitus and hypertension. Endocr J. 2013; 60(8): 967-976. doi: 10.1507/endocrj.EJ13-0060
8. Akehi Y, Kawate H, Murase K, et al. Proposed diagnostic criteria for subclinical Cushing’s syndrome associated with adorenal incidentaloma. Endocr J. 2013; 60(7): 903-912. doi: 10.1507/endocrj.EJ12-0458
9. Terawaki Y, Nomiyama T, Akehi Y, et al. The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis. Diabetology and Metab Synd. 2013; 5(1): 10. doi: 10.1186/1758-5996-5-10
10. Ervinna N, Mita T, Yasunari E, et al. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology. 2013; 154(3): 1260-1270. doi: 10.1210/en.2012-1855
11. Nagaishi R, Nomiyama T, Okamura A, et al. Efficacy and Safety of DPP-4 Inhibitor Linagliptin in Japanese Patients with Type 2 Diabetes. Prog Med. 2012; 32: 2225-2230.
12. Nomiyama T, Akehi Y, Yanase T. Diabetes in other diseases and conditions. Nihon Rinsho. 2012; 70(Suppl 3): 414-417. doi: 22768556
13. Noda K, Zhang B, Iwata A, et al. Lifestyle changes through the use of delivered meals and dietary counseling in a single-blind study: the STYLIST study. Circ J. 2012; 76(6): 1335-1344. doi: 10.1253/circj.CJ-12-0164
14. Mita T, Azuma K, Goto H, et al. IRS-2 deficiency in macrophages promotes their accumulation in the vascular wall. Biochem Biophys Res Commun. 2011; 415(4): 545-550. doi: 10.1016/j.bbrc.2011.10.086
15. Nomiyama T, Akehi Y, Takenoshita H, et al. Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2012; 95(2): e27-e28. doi: 10.1016/j.diabres.2011.08.016
16. Gizard F, Zhao Y, Findeisen HM, et al. Transcriptional regulation of the S-Phase kinase-associated protein 2 by the NR4A orphan nuclear receptor NOR1 in vascular smooth muscle cells. J Biol Chem. 2011; 286(41): 38485-38493. doi: 10.1074/jbc.M111.295840
17. Goto H, Nomiyama T, Mita T, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun. 2011; 405(1): 71-84. doi: 10.1016/j.bbrc.2010.12.131
18. Zhao Y, Howatt DA, Gizard F, et al. Deficiency of the NR4A orphan nuclear receptor NOR1 decreases monocyte adhesion and atherosclerosis. Circ Res. 2010; 107(4): 501-511. doi: 10.1161/CIRCRESAHA.110.222083
19. Mita T, Goto H, Azuma K, et al. Impact of insulin resistance on enhanced monocyte adhesion to endothelial cells and atherosclerosis independeny of LDL cholesterol level. Biochem Biophys Res Commun. 2010; 395(4): 477-483. doi: 10.1016/j.bbrc.2010.04.031
20. Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes. 2010; 59(4): 1030-1037. doi: 10.2337/db09-1694
21. Nomiyama T, Watada H. ARB as a drug for diabetic microangiopathy. Nihon Rinsho. 2009; 67(4): 777-782.
22. Tamura Y, Watada H, Tanaka Y, et al. Preliminary report: mitochondrial DNA 5178 polymorphism in male elite Japanese endurance runners. Matabolism. 2009; 59(1): 62-63. doi: 10.1016/j.metabol.2009.07.005
23. Nomiyama T, Zhao Y, Gizard F, et al. Deficiency of the NR4A Neuron-Derived Orphan Receptor-1 Attenuates Neointima Formation After Vascular Injury. Circulation. 2009; 119(4): 577-586. doi: 10.1161/CIRCULATIONAHA.108.822056
24. Gizard F, Nomiyama T, Zhao Y, et al. The PPAR (alpha)/p16INK4a Pathway Inhibits Vascular Smooth Muscle Cell Proliferation by Repressing Cell Cycle-Dependent Telomerase Activation. Circ Res. 2008; 103(10): 1155-1163. doi: 10.1161/CIRCRESAHA.108.186205
25. Nomiyama T, Bruemmer D. Liver X receptor as therapeutic targets in metabolism and atherosclerosis. Curr Atheroscler Rep. 2008; 10(1): 88-95. doi: 10.1007/s11883-008-0013-3
26. Nomiyama T, Perez-Tilve D, et al. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest. 2007; 117(10): 2877-2888. doi: 10.1172/JCI31986
27. Nakamachi T, Nomiyama T, Gizard F, et al. PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes. Diabetes. 2007; 56(6): 1662-1667. doi: 10.2337/db06-1177
28. Tamura Y, Ogihara T, Uchida T, et al. Amelioration of glucose tolerance by hepatic inhibition of nuclear factor kappaB in db/db mice. Diabetologia. 2007; 50(1): 131-141. doi: 10.1007/s00125-006-0467-1
29. Kapoor M, Nomiyama T, Bruemmer D, Kojima F, Crofford LJ. Growth factors and cytokines: Emphasis on their role in wound healing and atherosclerosis. Current Anesthesia & Critical Care. 2006; 17: 13-20. doi: 10.1016/j.cacc.2006.02.002
30. Nomiyama T, Nakamachi T, Gizard F, et al. The NR4A orphan nuclear receptor NOR1 is induced by platelet-derived growth factor and mediates vascular smooth muscle cell proliferation. J Biol Chem. 2006; 281(44): 33467-33476. doi: 10.1074/jbc.M603436200
31. Mita T, Watada H, Ogihara T, et al. Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. Atherosclerosis. 2007; 191(1): 162-167. doi: 10.1016/j.atherosclerosis.2006.03.005
32. Ogawa D, Nomiyama T, Nakamachi T, et al. Activation of Peroxisome Proliferator-Activated Receptor {gamma} Suppresses Telomerase Activity in Vascular Smooth Muscle Cells. Circ Res. 2006; 98(7): e50-e59. doi: 10.1161/01.RES.0000218271.93076.c3
33. Nishiyama K, Tanaka Y, Nakajima K, et al. Polymorphism of the solute carrier family 12 (sodium/chloride transporters) member 3, SLC12A3, gene at exon 23 (+78G/A: Arg913Gln) is associated with elevation of urinary albumin excretion in Japanese patients with type 2 diabetes: a 10-year longitudinal study. Diabetologia. 2005; 48(7): 1335-1338. doi: 10.1007/s00125-005-1785-4
34. Watada H, Nomiyama T, Kawamori R. Mechanism of progression of atherosclerosis in patients with impaired glucose tolerance (IGT). Nihon Rinsho. 2005; 63 Suppl 2: 101-106.
35. Takayanagi N, Onuma T, Kato S, Nishiyama K, Nomiyama T, Kawamori R. Association between LDL particle size and postprandial increase of remnant-like particles in Japanese type 2 diabetic patients. Diabetes Res Clin Pract. 2004; 66(3): 245-252. doi: 10.1016/j.diabres.2004.04.002
36. Nomiyama T, Igarashi Y, Taka H, et al. Deterioration of Insulin Stimulated Glucose Uptake by Peroxynitrite is Associated with Tyrosine-nitration of Insulin Receptor Substrate-1. Biochem Biophys Res Commun. 2004; 320(3): 320: 639-647.
37. Shimo-Nakanishi Y, Hasebe T, Suzuki A, et al. Functional effects of NAD(P)H oxidase p22phox C242T mutation in human leukocytes and association with thrombotic cerebral infarction. Atherosclerosis. 2004; 175: 109-115. doi: 10.1016/j.atherosclerosis.2004.01.043
38. Nomiyama T, Tanaka Y, Piao L, et al. Accumulation of Somatic Mutation in mitochondrial DNA and Atherosclerosis in Diabetic Patients. Ann NY Acad Sci. 2004; 1011: 193-204. doi: 10.1007/s00125-002-0893-7
39. Ogihara T, Watada H, Kanno R, et al. p38 mitogen-activated protein kinase is involved in activin A- and HGF-mediated expression of pro-endocrine gene neurogenin 3 in AR42J-B13 cells. J Biol Chem. 2003; 278(24); 21693-21700. doi: 10.1074/jbc.M302684200
40. Takagi M, Tanaka Y, Yamasaki Y, et al. Responsiveness of insulin-induced cardiac sympathetic nerve activation associates with blood pressure regulation in diabetics. Am J Physiol Endocrinol Metab. 2003; 284(5): E1022-E1026. doi: 10.1152/ajpendo.00169.2002
41. Nakajima K, Tanaka Y, Nomiyama T, et al. RANTES Promoter Genotype Is Associated With Diabetic Nephropathy in Type 2 Diabetic Subjects. Diabetes Care. 2003; 26(3): 892-898. doi: 10.2337/diacare.26.3.892
42. Nomiyama T, Tanaka Y, Piao L, et al. The polymorphism of manganese superoxide dismutase is associated with diabetic nephropathy in Japanese type 2 diabetic patients. J Hum Genet. 2003; 48(3): 138-141.
43. Piao L, Tanaka Y, Nomiyama T, et al. Combined Genotypes of ACE and NADPH Oxidase p22phox Associated with Somatic Mutation of mtDNA and Carotid Intima-Media Thickness in Japanese Patients with Type 2 Diabetes Mellitus. Curr Ther Res. 2002; 63(12): 842-852. doi: 10.1016/S0011-393X(02)80089-3
44. Nomiyama T, Tanaka Y, Hattori N, et al. Accumulation of somatic mutation in mitochondrial DNA extracted from peripheral blood cells in diabetic patients. Diabetologia. 2002; 45(11): 1577-1583. doi: 10.1007/s00125-002-0893-7
45. Nomiyama T, Kawamori R, Hattori N. Pathogenesis and contribution of mitochondria to diabetes or deafness. Nihon Rinsho. 2002; 60 Suppl 4: 273-277.
46. Nakajima K, Tanaka Y, Nomiyama T, et al. Chemokine receptor genotype is associated with diabetic nephropathy in Japanese with type 2 diabetes. Diabetes. 2002; 51(1): 238-242. doi: 10.2337/diabetes.51.1.238
47. Matsunaga H, Tanaka Y, Tanaka M, et al. Antiatherogenic mitochondrial genotype in patients with type 2 diabetes. Diabetes Care. 2001; 24(3): 500-503. doi: 10.2337/diacare.24.3.500